Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology
Imaging technology used by pharma firms could be more sensitive following research based on mass spectrometry

Bioanalytical

Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology

14 Jul, 2010

Published over 16 years ago. See the latest and most current information on Bioanalytical.

Research being conducted at Case Western Reserve University aims for a 1,000-fold enhancement of the mass spectrometry-based structural imaging technology used by pharma developers.

Dr Mark Chance, director of the university's school of medicine's Centre for Proteomics and Bioinformatics, explains that examining the structure of G-protein coupled receptors and similar membrane proteins is difficult.

However, pharma developers must determine how drugs are able to switch on and off those receptors if they are able to create therapeutics for diabetes, heart failure and depression.

Using mass spectrometry techniques, Dr Chance and his team succeeded in capturing a high-resolution image of the open state of a potassium channel, enabling analysis of gating mechanisms with applications in nerve signalling and heart function.

The 1,000-fold enhancement in imaging is one of the primary aims of the group led by Dr Chance, whose research focuses on the potential of structural genomics initiatives made possible by high-throughput analysis.

Latest News

Explore Our Other Sites

Labmate Online
Mayo Clinic and Thermo Fisher Scientific launch Precure LLC to identify signs of disease before their symptoms appear
Explore more Arrow
Envirotech Online
Connected safety technology company announces CEO appointment and leadership transition
Explore more Arrow
Pollution Solutions Online
Smarter wastewater management helps futureproof distillery operations and protect local watercourses
Explore more Arrow
Petro Online
Improving repeatability in diesel fuel lubricity testing
Explore more Arrow